Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025)
Inhibikase Therapeutics (IKT) reported Depreciation & Amortization (CF) of $23688.0 for Q3 2025, up 260.66% year-over-year from $6568.0 in Q3 2024, and down 1.94% quarter-over-quarter from $24157.0 in Q2 2025.
Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $23688.0 in Q3 2025.
- Depreciation & Amortization (CF) for Q3 2025 came in at $23688.0, up 260.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $47845.0 (up 47.86% YoY), and the FY2025 annual result was $60499.0, up 130.28% from the prior year.
- Depreciation & Amortization (CF) slipped to $23688.0 in Q3 2025 per IKT's latest filing, from $24157.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $159204.0 in Q2 2023 and troughed at $1681.0 in Q3 2022.
- A 4-year average of $20836.7 and a median of $6568.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) surged 290.72% in 2023, then tumbled 95.87% in 2024.
- A 4-year view of Depreciation & Amortization (CF) shows it stood at $5042.0 in 2022, then soared by 30.27% to $6568.0 in 2023, then fell by 0.02% to $6567.0 in 2024, then jumped by 260.71% to $23688.0 in 2025.
- Business Quant data shows IKT's Depreciation & Amortization (CF) at $23688.0 in Q3 2025, $24157.0 in Q2 2025, and $12654.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 23,688.00 |
| Sep 30, 2025 | 23,688.00 |
| Jun 30, 2025 | 24,157.00 |
| Jun 30, 2025 | 24,157.00 |
| Mar 31, 2025 | 12,654.00 |
| Mar 31, 2025 | 12,654.00 |
| Dec 31, 2024 | 6,567.00 |
| Dec 31, 2024 | 6,567.00 |
| Sep 30, 2024 | 6,568.00 |
| Sep 30, 2024 | 6,568.00 |
| Jun 30, 2024 | 6,569.00 |
| Jun 30, 2024 | 6,569.00 |
| Mar 31, 2024 | 6,568.00 |
| Mar 31, 2024 | 6,568.00 |
| Dec 31, 2023 | 6,568.00 |
| Dec 31, 2023 | 6,568.00 |
| Sep 30, 2023 | 6,568.00 |
| Sep 30, 2023 | 6,568.00 |
| Jun 30, 2023 | 159,204.00 |
| Jun 30, 2023 | 159,204.00 |